Related Experiment Video
Updated: Jul 26, 2025
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
William J Gradishar1, Meena S Moran2, Jame Abraham3
1Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Summary
The NCCN Guidelines for Breast Cancer offer updated systemic therapy recommendations for stage IV disease. These insights reflect the evolving treatment landscape for metastatic breast cancer, prioritizing patient survival.
Area of Science:
- Oncology
- Medical Guidelines
Background:
- The management of breast cancer is complex and continually evolving.
- Metastatic breast cancer treatment strategies are increasingly personalized based on tumor biology and biomarkers.
- Advances in systemic therapies offer improved survival outcomes for patients with advanced disease.
Purpose of the Study:
- To provide an overview of recent updates to the NCCN Clinical Practice Guidelines for Breast Cancer.
- To focus specifically on systemic therapy recommendations for patients diagnosed with stage IV (M1) metastatic breast cancer.
- To highlight the dynamic nature of breast cancer treatment and the availability of subsequent lines of therapy.
Main Methods:
- Review of the latest NCCN Clinical Practice Guidelines for Breast Cancer.
- Analysis of systemic therapy recommendations for metastatic (stage IV) breast cancer.
- Focus on updates relevant to current clinical practice and evolving treatment options.
Main Results:
- The NCCN Guidelines for Breast Cancer provide comprehensive management strategies.
- Recent updates focus on systemic therapies for stage IV disease.
- Personalized therapeutic approaches considering tumor biology and biomarkers are emphasized.
Conclusions:
- The NCCN Guidelines offer crucial updates for managing metastatic breast cancer.
- Evolving treatment options ensure subsequent lines of therapy are available.
- These guidelines support improved survival for patients with stage IV breast cancer.
